MEGESTROL-ACETATE REVERSES MULTIDRUG RESISTANCE AND INTERACTS WITH P-GLYCOPROTEIN

被引:63
|
作者
FLEMING, GF [1 ]
AMATO, JM [1 ]
AGRESTI, M [1 ]
SAFA, AR [1 ]
机构
[1] UNIV CHICAGO,MED CTR,DEPT MED,HEMATOL ONCOL SECT,5841 S MARYLAND AVE,MC2115,CHICAGO,IL 60637
关键词
MEGESTROL; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN;
D O I
10.1007/BF00684845
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100-mu-M, both steroids inhibited the binding of a Vinca alkaloid photoaffinity analog to P-glycoprotein (P-gp) in MDR human neuroblastic SH-SY5Y/VCR cells [which show > 1500-fold resistance to vincristine (VCR) in the tetrazolium dye (MTT) assay]. However, 100-mu-M MA markedly enhanced the binding of [H-3]-azidopine to P-gp in both SH-SY5Y/VCR cells and the MDR human epidermoid KB-GSV2 cell line (which displays 250-fold resistance to VCR in the MTT assay). PRG had little effect on the binding of [H-3]-azidopine to P-gp. MA at low doses was more effective than PRG in sensitizing cells to VCR and enhancing their accumulation of [H-3]-VCR. The highly resistant SH-SY5Y/VCR subline exhibited significant collateral sensitivity to both steroids. These data suggest that MA may be a clinically useful modulator of MDR.
引用
收藏
页码:445 / 449
页数:5
相关论文
共 50 条
  • [31] Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression
    Luo, Fei
    Li, Huiyu
    Liang, Jianfang
    Jia, Hongyan
    Li, Xiaoyu
    Xiao, Hong
    He, Xuehua
    He, Jiefeng
    Tian, Yanzhang
    Zhao, Haoliang
    [J]. MOLECULAR MEDICINE REPORTS, 2017, 15 (04) : 2360 - 2368
  • [32] Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein
    Yinxu Zhang
    Xiaomei Liu
    Teng Zuo
    Yu Liu
    Jun Hua Zhang
    [J]. Medical Oncology, 2012, 29 : 534 - 538
  • [33] Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
    Zhou, Wen-jing
    Zhang, Xu
    Cheng, Chao
    Wang, Fang
    Wang, Xiao-kun
    Liang, Yong-ju
    To, Kenneth Kin Wah
    Zhou, Wang
    Huang, Hong-bing
    Fu, Li-wu
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (05) : 1669 - 1683
  • [34] INTERACTION OF TAMOXIFEN WITH THE MULTIDRUG-RESISTANCE P-GLYCOPROTEIN
    CALLAGHAN, R
    HIGGINS, CF
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (02) : 294 - 299
  • [35] Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein
    Zhang, Yinxu
    Liu, Xiaomei
    Zuo, Teng
    Liu, Yu
    Zhang, Jun Hua
    [J]. MEDICAL ONCOLOGY, 2012, 29 (02) : 534 - 538
  • [36] Molecular dissection of the human multidrug resistance P-glycoprotein
    Loo, TW
    Clarke, DM
    [J]. BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1999, 77 (01): : 11 - 23
  • [37] P-GLYCOPROTEIN AND MULTIDRUG RESISTANCE IN CANCER-CHEMOTHERAPY
    DEUCHARS, KL
    LING, V
    [J]. SEMINARS IN ONCOLOGY, 1989, 16 (02) : 156 - 165
  • [38] P-GLYCOPROTEIN, MULTIDRUG-RESISTANCE AND TUMOR PROGRESSION
    BRADLEY, G
    LING, V
    [J]. CANCER AND METASTASIS REVIEWS, 1994, 13 (02) : 223 - 233
  • [39] Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
    Zhou, Wen-jing
    Wang, Fang
    Zhang, Xu
    To, Kenneth Kin Wah
    Huang, Hong-bing
    Fu, Li-Wu
    [J]. CANCER RESEARCH, 2012, 72
  • [40] Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
    Sikic, BI
    Fisher, GA
    Lum, BL
    Halsey, J
    BeketicOreskovic, L
    Chen, G
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) : S13 - S19